NVO NOVO NORDISK A S IFRS Annual reports only
Pharmaceutical Preparations · NYSE · SEC CIK 353278 · Reporting currency DKK · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: DKK | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 309.06B | 290.40B | 232.26B | 176.95B | 140.80B |
| Cost of revenue | 58.79B | 44.52B | 35.77B | 28.45B | 23.66B |
| Gross profit | 250.28B | 245.88B | 196.50B | 148.51B | 117.14B |
| R&D expense | 52.04B | 48.06B | 32.44B | 24.05B | 17.77B |
| Operating income | 127.66B | 128.34B | 102.57B | 74.81B | 58.64B |
| Interest expense | 4.21B | 1.64B | 542.00M | 378.00M | 289.00M |
| Pretax income | 130.54B | 127.19B | 104.67B | 69.06B | 59.08B |
| Income tax | 28.11B | 26.20B | 20.99B | 13.54B | 11.32B |
| Net income | 102.43B | 100.99B | 83.68B | 55.52B | 47.76B |
| EBITDA | 142.32B | 136.88B | 109.86B | 81.36B | — |
| EPS (basic) | 23.06 | 22.67 | 18.67 | 12.26 | 10.40 |
| EPS (diluted) | 23.03 | 22.63 | 18.62 | 12.22 | 10.37 |
| Weighted avg. shares (diluted) | 4.45B | 4.46B | 4.49B | 4.54B | 4.61B |
| Balance sheet | |||||
| Cash & equivalents | 26.46B | 15.65B | 14.39B | 12.65B | 10.72B |
| Receivables | 70.86B | 71.95B | 64.77B | 50.56B | 40.64B |
| Inventory | 49.62B | 40.85B | 31.81B | 24.39B | 19.62B |
| Current assets | 172.45B | 161.79B | 139.65B | 108.19B | 85.59B |
| PP&E, netmay include right-of-use assets (IFRS) | 208.38B | 161.68B | 90.96B | 66.67B | 55.36B |
| Goodwill | 19.84B | 20.02B | — | — | — |
| Intangibles | 110.21B | 90.80B | 60.41B | 50.94B | 43.17B |
| Total assets | 542.90B | 465.63B | 314.49B | 241.26B | 194.51B |
| Current liabilities | 215.66B | 217.61B | 169.66B | 120.94B | 99.52B |
| Short-term debt | 12.02B | 13.11B | 6.48B | 1.47B | 13.68B |
| Long-term debt | 118.94B | 89.67B | 20.53B | 24.32B | 12.96B |
| Total debt | 130.96B | 102.79B | 27.01B | 25.78B | 26.64B |
| Total liabilities | 348.86B | 322.14B | 207.93B | 157.77B | 123.76B |
| Shareholders' equity | 194.05B | 143.49B | 106.56B | 83.49B | 70.75B |
| Net debt | 104.49B | 87.13B | 12.61B | 13.13B | 15.93B |
| Shares outstanding | 4.44B | 4.44B | 4.46B | 4.50B | 4.62B |
| Cash flow statement | |||||
| Operating cash flow | 119.10B | 120.97B | 108.91B | 78.89B | 55.00B |
| Capital expenditure | 60.14B | 47.16B | 25.81B | 12.15B | 6.33B |
| Free cash flow | 58.96B | 73.80B | 83.10B | 66.74B | 48.66B |
| Investing cash flow | -79.16B | -128.90B | -43.89B | -24.92B | -31.61B |
| Financing cash flow | -28.41B | 8.73B | -63.16B | -51.80B | -25.49B |
| Depreciation & amortization | 14.67B | 8.54B | 7.29B | 6.55B | — |
| Stock-based compensation | 1.44B | 2.29B | 2.15B | 1.54B | 1.04B |
| Dividends paid | 51.76B | 44.14B | 31.77B | 25.30B | 21.52B |
| Share buybacks | 1.39B | 20.18B | 29.92B | 24.09B | 19.45B |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, DKK, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.